Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

被引:8
|
作者
Morganti, Stefania [1 ,2 ,3 ,4 ,5 ,6 ]
Bychkovsky, Brittany L. [1 ,2 ,3 ,7 ]
Poorvu, Philip D. [1 ,2 ,3 ]
Garrido-Castro, Ana C. [1 ,2 ,3 ,4 ]
Weiss, Anna [8 ]
Block, Caroline C. [1 ,2 ,3 ]
Partridge, Ann H. [1 ,2 ,3 ]
Curigliano, Giuseppe
Tung, Nadine M. [3 ,9 ]
Lin, Nancy U. [1 ,2 ,3 ]
Garber, Judy E. [1 ,2 ,3 ]
Tolaney, Sara M. [1 ,2 ,3 ]
Lynce, Filipa [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Broad Inst MIT & Harvard, Boston, MA USA
[5] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev, Milan, Italy
[6] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[7] Dana Farber Canc Inst, Div Genet & Prevent Program, Boston, MA 02115 USA
[8] Univ Rochester, Dept Surg, Div Surg Oncol, Rochester, NY USA
[9] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
来源
ONCOLOGIST | 2023年 / 28卷 / 07期
关键词
germline BRCA; early breast cancer; olaparib; adjuvant; OlympiA; OPEN-LABEL; HIGH-RISK; CHEMOTHERAPY; MUTATION; CAPECITABINE; SURVIVAL; PEMBROLIZUMAB; ESTROGEN; OUTCOMES; WOMEN;
D O I
10.1093/oncolo/oyad123
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. The benefit was consistent across subgroups, and this regimen is now recommended after chemotherapy for germline BRCA1/2 mutation (gBRCA1/2m) carriers with high-risk, HER2-negative early breast cancer. However, the integration of olaparib in the landscape of agents currently available in the post(neo) adjuvant setting-ie, pembrolizumab, abemaciclib, and capecitabine-is challenging, as there are no data suggesting how to select, sequence, and/or combine these therapeutic approaches. Furthermore, it is unclear how to best identify additional patients who could benefit from adjuvant olaparib beyond the original OlympiA criteria. Since it is unlikely that new clinical trials will answer these questions, recommendations for clinical practice can be made through indirect evidence. In this article, we review available data that could help guide treatment decisions for gBRCA1/2m carriers with high-risk, early-stage breast cancer.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 50 条
  • [1] Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
    Morganti, Stefania
    Jin, Qingchun
    Vincuilla, Julie
    Buehler, Ryan
    Ryan, Sean
    Stokes, Samantha
    Parker, Tonia
    Mittendorf, Elizabeth A.
    King, Tari A.
    Weiss, Anna
    Partridge, Ann H.
    Bychkovsky, Brittany L.
    Curigliano, Giuseppe
    Tayob, Nabihah
    Lin, Nancy U.
    Garber, Judy E.
    Tolaney, Sara M.
    Lynce, Filipa
    NPJ BREAST CANCER, 2024, 10 (01)
  • [2] Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer
    Takamizawa, Shigemasa
    Ishiki, Hiroto
    Shimoi, Tatsunori
    Shimizu, Masaki
    Satomi, Eriko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23)
  • [3] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
    McCrea, Charles
    Hettle, Robert
    Gulati, Poonam
    Taneja, Ankush
    Rajora, Preety
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
  • [4] Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
    Cedillo, Sergio
    Gonzalez-Dominguez, Almudena
    Ivanova-Markova, Yoana
    Lopez, Rafael Lopez
    Cobo, Sara Lopez-Tarruella
    Pedrosa, Jose Alberto Pena
    PHARMACOECONOMICS-OPEN, 2024, 8 (06) : 887 - 896
  • [5] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Domchek, Susan M.
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Armstrong, Anne
    Conte, Pierfranco
    Bannister, Wendy
    Goessl, Carsten
    Runswick, Sarah
    Goel, Saurabh
    Tung, Nadine
    CANCER RESEARCH, 2018, 78 (04)
  • [6] Cost-effectiveness for companion BRCA testing and adjuvant olaparib treatment in patients with BRCA mutated high-risk HER2-negative early breast cancer
    Sheppard, E.
    Ma, W.
    Punekar, Y.
    Sagoo, G.
    Nikolova, S.
    VIRCHOWS ARCHIV, 2024, 485 : S347 - S347
  • [7] Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2negative breast cancer and potential eligibility for adjuvant Olaparib
    Morganti, Stefania
    Jin, Qingchun
    Vincuilla, Julie
    Buehler, Ryan
    Ryan, Sean
    Stokes, Samantha
    Parker, Tonia
    Mittendorf, Elizabeth A.
    King, Tari
    Weiss, Anna
    Partridge, Ann
    Bychkovsky, Brittany
    Curigliano, Giuseppe
    Tayob, Nabihah
    Lin, Nancy U.
    Garber, Judy
    Tolaney, Sara
    Lynce, Filipa
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).
    Meisner, Eleanor
    Rollins, Rebecca
    Ensor, Joe
    Moran, Amber
    Woodward, Amanda
    Ahn, Eugene R.
    Lynch, Cynthia Anne
    Citrin, Dennis L.
    Hansra, Damien
    Aithal, Sramila S.
    Ninan, Mary
    Nixon, Daniel W.
    Zook, Susan
    Ali, Siraj Mahamed
    Markman, Maurie
    Alvarez, Ricardo H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Adjuvant capecitabine for HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (07): : E375 - E375
  • [10] Early HER2-negative Breast Cancer - How often is BRCA Germline Testing useful without a family History?
    Klein, Friederike
    GYNAKOLOGIE, 2023, 56 (09): : 582 - 583